Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
Status:
Completed
Trial end date:
2019-04-22
Target enrollment:
Participant gender:
Summary
This study will characterize the pharmacokinetics (PK) of QAW039 after a single oral dose of
QAW039 in patients with hepatic impairment compared to healthy matched control subjects.